Showing results (161-170 of 199) with videos related to
Sort By:
Pageof 20
British Journal of Haematology|October 2, 2009
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow TransplantationIrit Avivi, Silvia Montoto, Carme Canals, et al.British Journal of Haematology|October 7, 2022
Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective studyTamir Shragai, Hila Magen, Noa Lavi, et al.British Journal of Haematology|May 10, 2017
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myelomaShaji Kumar, Philippe Moreau, Parameswaran Hari, et al.Transplantation and Cellular Therapy|July 2, 2021
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort StudyRon Ram, David Hagin, Nino Kikozashvilli, et al.European Journal of Haematology|March 25, 2023
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter studyOfrat Beyar Katz, Chava Perry, Sigal Grisariu-Greenzaid, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Efficacy and Safety of Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL AmyloidosisEyal Lebel, Nathalie Asherie, Shlomit Kfir-Erenfeld, et al.Blood|January 9, 2025
Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyMax S Topp, Matthew Matasar, John N Allan, et al.Cancer Research|October 10, 2025
Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell LymphomaAnna Gurevich-Shapiro, Pascale Zwicky, Eitan Winter, et al.Leukemia & Lymphoma|September 28, 2020
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceYafit Segman, Elena Ribakovsky, Abraham Avigdor, et al.American Journal of Hematology|July 24, 2019
Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patientsIrit Avivi, Yael C Cohen, Anna Suska, et al.Pageof 20